The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.
Omaha, Neb. – May 25, 2023 – Cassling has announced a partnership with the goal of benefitting cardiovascular practices throughout the United States.
Cassling will act as a sales agent for EchoSolv™, a revolutionary new cloud-based software from Echo IQ, an AI healthtech company. EchoSolv™, a proprietary artificial intelligence clinical decision support platform, supports cardiology practitioners in diagnosing structural heart disease.
Cassling is uniquely positioned to help healthcare providers understand the outcome-improving implications of this technology. Cassling has extensive expertise in the imaging and cardiovascular markets, and its Growth & Innovation team chose to partner with Echo IQ after listening closely to the needs of customers.
Like Cassling, Echo IQ is committed to creating measurable improvements in patient outcomes and provider experience, unlocking greater efficiencies and lowering costs for healthcare organizations who are asked to do more with less.
"We are excited to partner with Echo IQ and introduce what we believe will be a gamechanger for patients and care teams,” said Elizabeth Grieger, VP of Growth & Innovation at Cassling. “Aortic stenosis is often highly treatable, but accurate disease identification is critical. This innovative technology can be easily integrated into clinical practice and used both as an audit tool and to support real-time diagnosis.”
“We believe our customers will be eager to embrace EchoSolv™ as a means to improve access and outcomes and, ultimately, strengthen community healthcare.””
A recent clinical trial at St Vincent’s Hospital in Sydney, Australia, showed a 72% increase in the detection of severe in-guideline aortic stenosis among patients over cardiologists not using the EchoSolv™ platform. The study was based on 9,189 patients’ echocardiograms and concurred with similar results in previous clinical trials at St Vincent’s Hospital in Melbourne and Beth Israel Deaconess at Harvard Medical School.
“The appointment of Cassling as an agent in the US is highly significant given their impressive reputation in the market,” said Andrew Grover, Executive Chair of Echo IQ. “We are pleased to see our solution sit alongside their stellar offering of complementary products and services.”
Healthcare providers who are interested in learning more about this exciting artificial intelligence software can reach out to Jeff Weinrich, VP of Growth and Innovation Sales at email@example.com.
Cassling strengthens community healthcare through customer-centric imaging and therapeutic technology, services and solutions. From critical access hospitals and diagnostic imaging centers to large health systems and IDNs, Cassling is committed to helping healthcare organizations improve access and outcomes, create efficiencies and lower costs.
Cassling serves as a partner and strategic advisor to healthcare organizations—helping them navigate the challenges of the fast-paced, ever-changing healthcare industry. Through our partnerships, including Siemens Healthineers, Cassling offers the best of both worlds—an unprecedented level of service and local support in combination with world-class imaging technology. Our goal is to impact 350 million patient lives by 2030.
Headquartered in Omaha, Nebraska, and founded in 1984, Cassling is proud to be a family-owned company and have Midwestern values and integrity at the heart of what we do. To learn more, visit www.Cassling.com.
About Echo IQ
Echo IQ uses the AI-powered technology in EchoSolv™ to enhance the diagnosis of structural heart disease. Their mission is to help improve the lives of people by supporting earlier, more accurate detection of a number of life-threatening but often treatable conditions.
The Echo IQ screening program applies innovation and a proprietary algorithm to produce risk assessments for patients using their echocardiographic measurements. The power of AI is harnessed to produce consistent outputs at speed and without bias. Applied to the identification of aortic stenosis, EchoSolv™ has been designed to identify patients at risk of mortality who might benefit from further clinical review. Echo IQ is proud to be applying leading-edge technologies, led by thought leaders in cardiology, to deliver new solutions in cardiac care.
EchoSolv™ is currently available in the US and Australia as a guideline-led decision-support tool. Full phenotyping capabilities will be available pending FDA approval.
To learn more, visit https://www.echoiq.ai/.